The first patient to get a taste of Morocco collected the inaugural prescribed Beldiya Plus° picked up their prescription from legally authorized South African pharmacy Greenways Dispensary in Johannesburg on Friday, October 17, 2025, in full compliance with all necessary procedural and regulatory frameworks.
The prescription was issued by Dr. Anton Janse van Rensburg, Chief Medical Officer of Cannabis Clinics, based in Pretoria, South Africa, known for his expertise in medicinal cannabis and chronic pain management. The prescription and dispensing process was managed and facilitated through the Cannabis Clinics digital health platform, which streamlines access and regulatory compliance for both patients and prescribing doctors.
Cannaflex announced its first steps down south on 20 October 2025, saying that the South African deal is a milestone achievement and signals Morocco’s entry into the global medical cannabis market.
It says the export was made possible through a strategic partnership with South African pharmaceutical manufacturer DRA Pharmaceuticals, which specializes in compliance and pharmaceutical quality.
Canaflex obtained all necessary authorizations from the Moroccan Agency for Medicines and Health Products and the Autonomous Establishment for Export Control and Coordination. The shipment adhered fully to all legal and customs procedures, and was coordinated with Royal Air Maroc and international freight carriers.
Chris Hutton, CEO of DRA Pharmaceuticals says the company’s job was to ensure that Beldiya Plus met the strictest international standards and “provide safe, reliable and evidence-based therapies” for local patients. DRA has a GMP facility in Gauteng where Belidya Plus was tested. If has long supplied the pharmaceutical trade as it is a licenced scheduled medicine distributor and is known for taking on niche market projects.
The collaboration highlights how Moroccan producers are aligning with international regulations to access foreign markets. Industry observers see this as a critical validation of Morocco’s ability to deliver compliant, research-backed medical cannabis products beyond its borders.
The international breakthrough follows earlier domestic progress. In December 2024, Moroccan pharmaceutical company Pharma 5 launched Cannabidiol Pharma 5, the country’s first generic cannabis-based drug, developed under a MAD 250 million (US $27.1 million) investment. The drug, positioned as a revolutionary treatment for epilepsy, received national marketing authorization and will be launched in Moroccan pharmacies this year.
Last month, Morocco made its first medical cannabis shipments to Australia, signalling its entry into that market for the first time and introducing Beldiya and its potent thereapeutic compounds, to the world stage.
About Morocco’s Beldia/Beldiya Landrace
Beldiya, also spelled Beldia, is Morocco’s most prominent landrace, an ancient sativa that is well adapted to the harsh conditions of the Rif valley where it is cultivated. Also known as Kief, the strain is thought to be over 800 years old and has been used for decades to produce the old school blond/chocolaty Moroccan hash. Its sweet honey smell and delicate floral and minty taste are said to be unlike any other strain.
Beldiya is probably one of the fastest-flowering Sativas in the world, and although the THC percentages can vary wildly (5% to 45%), the rule of thumb has been that Badiya traditionally has three parts THC to one part CBD. Scientists say Baldiya has more chemical consistency than Morocco’s other main strains, Avocat, Mexicana, Critical Plus, and Khardala, which show considerable variability, displaying heterogeneity from one year to another. The earlier flowering stage of “Beldiya” compared to other varieties, prevents hybridization with exotic cultivars.
#
